Dr. Zbigniew Markowski has stepped down, for personal and family reasons, from his positions as chief executive officer of Helix BioPharma and chairman of Helix Polska. Helix BioPharma is a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer. Dr. Sven Rohmann will replace Markowski, effective immediately.
Dr. Rohmann, current Chairman of the Board of Helix, has served as a director of the Company since December 18, 2013 and has served as chair of several of the Company's governance committees.
Dr. Rohmann is an experienced biotech entrepreneur and pharma manager and a life science venture capitalist with more than 30 years hands-on experience in preclinical and clinical research as well as marketing, business and corporate development, especially in the field of oncology. Dr. Rohmann, together with Dr. Orlowski, another member of Helix's board, led the Adiuvo Investment team as CEO. In addition, Dr. Rohmann was instrumental in building the oncology franchise of Merck Serono where he served as the Business Area Head Oncology, as well as franchise`s global head, Strategic Marketing, and was involved in the in-licensing of Erbitux, an oncology blockbuster drug, from Imclone.
Rohmann was the founding CEO of Ganymed Pharmaceuticals, a German oncology startup company, now employing about 80 people with six development leads up into clinical phase IIb.
As a Venture Capital Fund Manager, Dr. Rohmann worked for the U.S. headquartered Burrill & Company, as well as for the Swiss-based Nextech Venture and Novartis Pharma, where he was involved in establishing a dedicated oncology fund. At Novartis Pharma, a portion of his time also involved being head of Partnering, General Medicine and Mature Products. Dr Rohmann obtained his medical degree and Ph.D. from the Universities of Mainz, Germany, and Rotterdam, Netherlands, respectively.